Two Omaha women lost more than 300 lbs. combined with injections of a GLP-1 drug, which are used increasingly for weight loss ...
The obesity market size is projected to witness growth from 2024 to 2034 due to the rising prevalence of obesity. This expansion is expected to be fu ...
Hims & Hers Health, Inc. is a dramatically undervalued company if your holding period can be measured in decades. Read more ...
The agency first declared a shortage of semaglutide, the main ingredient used to make Ozempic and Wegovy, in 2022.
Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...
A randomized, placebo-controlled trial validates a side effect frequently observed by doctors and patients. A new study from ...
Federal regulators say shortages of Ozempic and Wegovy have been resolved, as supplies of popular diabetes and obesity ...
The shortage of Novo Nordisk’s (NVO) blockbuster diabetes and weight-loss drugs is officially over, according to the U.S.
The FDA has declared an end to the shortage of Novo Nordisk’s blockbuster drug semaglutide, threatening the ability for ...
According to the FDA, there is no longer a shortage of semaglutide, the active ingredient in the wildly popular Ozempic and Wegovy — a very bad omen for the countless telehealth and pharmacy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback